Gland Pharma has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.
The company has reported 44.99% rise in its net profit at Rs 420.45 crore for the quarter under review as compared to Rs 289.99 crore for the same quarter in the previous year. The total income of the company has increased by 27.36% at Rs 1,367.95 crore for Q4FY26 as compared to Rs 1,074.07 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 96.57% jump in its net profit at Rs 366.68 crore for the fourth quarter ended March 31, 2026 as compared to Rs 186.54 crore for the same quarter in the previous year. The total income of the company increased by 26.23% at Rs 1,854.26 crore for Q4FY26 as compared to Rs 1,468.94 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported 19.25% rise in its net profit at Rs 1,299.55 crore as compared to Rs 1,089.75 crore for the previous year. The total income of the company has increased by 12.12% at Rs 4,855.99 crore for year under review as compared to Rs 4,331.22 crore for year ended March 31, 2025.
For the year ended March 31, 2026, on the consolidated basis, the company has reported 47.07% rise in its net profit at Rs 1,027.32 crore as compared to Rs 698.53 crore for the previous year. The total income of the company increased by 15.73% at Rs 6,746.98 crore for year under review as compared to Rs 5,830.11 crore for year ended March 31, 2025.
